Greg Di Russo, MD

Greg Di Russo is the Chief Medical Officer (CMO) at Kriya. Prior to becoming CMO in 2025, Greg spent ten years at Pfizer, most recently as Development Head, Non-Malignant Hematology, where he led the development of Pfizer’s hemophilia and sickle cell disease portfolios, including having oversight of the gene therapies BEQVEZ™ and giroctocogene fitelparvovec, as well as multiple associated global regulatory filings. Prior to Pfizer, he held development roles at CSL Behring and Bristol-Meyers Squibb overseeing global clinical programs. Before joining industry, Dr. Di Russo practiced congenital cardiothoracic surgery at the University of Utah and Children’s National Hospital in Washington, D.C.

Dr. Di Russo received his MD from Sidney Kimmel Medical College and his AB in romance languages from Princeton University.